GenVivo Reports Positive Phase 1 Results for GEN2 Off-the-Shelf Cancer Immunotherapy
核心洞察
GenVivo (搜索)'s GEN2 demonstrated strong safety profile with no dose-limiting toxicity or treatment-related discontinuations in 23 patients with advanced solid tumors (搜索).
The off-the-shelf mRNA vector showed dose-dependent increases in immunocytokines and vector persistence, confirming its dual mechanism of action through HSV-eTK (搜索) and GM-CSF.
GEN2's intravenous administration offers significant advantages over intratumoral approaches by enabling treatment of advanced disease with distant metastases.
GenVivo (搜索) has reported encouraging Phase 1 clinical trial results for GEN2, an innovative off-the-shelf cancer (搜索) immunotherapy that activates patients' immune systems against their entire tumor antigen repertoire. The data, presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, demonstrate the therapy's safety profile and biological activity in 23 patients with advanced solid tumors (搜索).
Strong Safety Profile Across Dose Levels
The Phase 1 dose-escalation study (NCT06391918) evaluated GEN2 across five intravenous dose levels ranging from 3.4 × 10⁶ to 2 × 10⁸ TU/kg in combination with valganciclovir (VGCV (搜索)). The therapy demonstrated excellent tolerability with no dose-limiting toxicity observed and no treatment-related discontinuations reported.
Treatment-related adverse events were predominantly mild, including diarrhea (22%), nausea (17%), vomiting and fatigue (13% each), all Grade 1-2. Stable disease lasting more than 24 weeks was observed in some patients, indicating potential clinical benefit.
Dual Mechanism of Action Validated
GEN2 operates through a sophisticated dual-mechanism approach using a non-replicating mRNA vector that delivers two payload genes: an enhanced prodrug-activator enzyme (HSV-eTK (搜索)) and an immunostimulatory cytokine (GM-CSF). Following VGCV (搜索) prodrug administration, GEN2 triggers local release of tumor-specific antigens, including neoantigens, to stimulate immune responses.
Pharmacodynamic and biomarker data confirmed GEN2's mechanism of action. Dose-dependent increases in GM-CSF were observed with intravenous administration, while levels of IL-2, IFN-γ (搜索), CCL4 (搜索), and CCL3 (搜索) showed increasing trends, indicating GEN2-induced biological activity. Vector persistence in peripheral blood mononuclear cells confirmed transgene expression, and elimination of the signal after VGCV (搜索) administration demonstrated the effectiveness of the prodrug-activated enzyme.
Neutralizing Antibody Challenge Identified
A key finding emerged regarding neutralizing antibody development at higher dose levels. Cycle 2 Day 1 data showed lower exposure compared to Cycle 1 at higher doses, coincident with neutralizing antibody development. GenVivo (搜索) is evaluating alternate dosing schedules and premedication strategies to mitigate this immune response.
"GEN2 represents a unique systemic treatment modality employing an 'off-the-shelf' gene delivery vector that exerts immunotherapeutic effects through multiple mechanisms of action," said Dr. Anthony El-Khoueiry, Chief of the Section of Developmental Therapeutics and Verna R. Richter Chair in Cancer (搜索) Research at the University of Southern California Norris Comprehensive Cancer Center. "These data verified GEN2's gene transduction, consistent with its putative mechanism of action, resulting in increased cytokine and immunomodulatory protein biomarkers, and creating the potential to promote an anti-tumor immune response."
Systemic Administration Advantage
GEN2's intravenous administration represents a significant advancement over alternative therapies limited by intratumoral or intralesional approaches. While clinical trials of oncolytic viruses or replication-deficient vectors have shown encouraging results in skin, bladder, prostate, pancreatic, and lung cancers, local administration is typically restricted to readily accessible tumors. GEN2's systemic delivery enables treatment of advanced disease with distant metastases, addressing a critical unmet medical need.
Platform Validation and Pipeline Development
Dr. Robert G. Johnson, Chief Operating Officer of GenVivo (搜索), emphasized the broader implications: "The GEN2's pharmacokinetic, pharmacodynamic, and safety data together with the demonstration of the effectiveness of the 'off'-switch provide clinical validation of GenVivo's G-Volve™ vector platform, the basis for GEN2. The GEN2 data provide a solid foundation for advancing our G-Volve™ platform, including IL-12 (搜索) and in vivo CAR-T vector programs."
The company's pipeline includes GEN-1013, an IL-12 (搜索) encoding therapy, and an in vivo CAR-T vector program, all built on the validated G-Volve™ platform. A parallel intratumoral cohort continues in cutaneous malignancies (搜索), expanding the therapeutic applications.
GEN2's off-the-shelf approach eliminates the need for tumor biopsies or tumor-specific genomic sequencing to identify patient-specific neoantigens, enabling faster treatment initiation compared to personalized immunotherapies. This represents a significant operational advantage in clinical practice, potentially improving patient access to advanced cancer (搜索) immunotherapy.